{"id":59262,"date":"2024-09-10T12:04:31","date_gmt":"2024-09-10T12:04:31","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2024\/09\/10\/new-secondary-analysis-of-phase-3-data-demonstrates-sotagliflozin-improves-time-in-range-tir-and-several-parameters-of-glucose-control-and-variability-in-basal-insulin-treated-type-2-diabetes\/"},"modified":"2024-09-10T12:04:31","modified_gmt":"2024-09-10T12:04:31","slug":"new-secondary-analysis-of-phase-3-data-demonstrates-sotagliflozin-improves-time-in-range-tir-and-several-parameters-of-glucose-control-and-variability-in-basal-insulin-treated-type-2-diabetes","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/new-secondary-analysis-of-phase-3-data-demonstrates-sotagliflozin-improves-time-in-range-tir-and-several-parameters-of-glucose-control-and-variability-in-basal-insulin-treated-type-2-diabetes\/","title":{"rendered":"New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes"},"content":{"rendered":"
\n

Study results aligned with positive clinical trial outcomes for type 1 diabetes treatment with sotagliflozin<\/em><\/strong>\u00a0\u00a0<\/p>\n

TIR measures approach target set by American Diabetes Association <\/em><\/strong><\/p>\n

Data to be presented at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain and online<\/em><\/strong><\/p>\n

THE WOODLANDS, Texas, Sept. 10, 2024 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc.<\/a> (Nasdaq: LXRX) today announced that data from the SOTA-INS CGM Phase 3 randomized clinical trial demonstrated that once-daily dosing of sotagliflozin 400 mg improved time-in-range (TIR) and several continuous glucose monitoring (CGM) parameters, including glucose variability, in insulin-treated type 2 diabetes (T2D) patients. Researchers also observed positive trends with the once-daily dose of 200 mg. Study findings will be presented September 12th<\/sup> at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain and online.<\/p>\n

The objective of the SOTA-INS CGM study was to evaluate the effect of sotagliflozin on TIR as assessed by CGM in people with T2D. The primary sub-study endpoint was mean change in percentage of time spent within TIR (glucose 70-180 mg\/dL [3.9-10.0 mmol\/L]) over 24 hours for sotagliflozin 400 mg versus placebo.<\/p>\n

The American Diabetes Association recommends a TIR target of at least 70% (17 hours) in people with type 1 diabetes (T1D) or T2D. In this study, sotagliflozin 200 mg and 400 mg once daily TIR (15.3 and 15.9 hours, respectively) approached the ADA target, with modest reductions in time-above-range (TAR) and mild increases in time-below-range (TBR).<\/p>\n

Sotagliflozin has previously demonstrated glycemic efficacy and improvements in TIR as an adjunct to insulin therapy in people with T1D who participated in the inTandem clinical trial program.<\/p>\n

Details of the data presentation are as follows:\u00a0<\/p>\n